Neuropsychiatric Associations of Mast Cell Activiation Syndrome and its Implications with Mental Health and Depression

Michael-Christopher Suman
Mentored Research with Jenny M. Montejo, M.D., Mayo Clinic

***Abstract*–Mast Cell Activation Syndrome (MCAS) is an underrecognized immunological disorder characterized by aberrant release of mast cell mediators affecting multiple organ systems. Beyond physical manifestations, patients frequently report psychiatric comorbidities including depression, anxiety, and cognitive impairment. This study reviews patient-reported outcomes, existing survey data, and published literature to explore the relationship between MCAS and mental health. Results indicate that elevated rates of depression and anxiety among MCAS patients may stem from both biological mechanisms—such as mast cell–derived cytokine release and histamine dysregulation—and psychosocial factors, including prolonged diagnostic uncertainty and chronic symptom burden. Evidence suggests that targeting mast cell activity may provide symptomatic relief beyond physical health, underscoring the need for interdisciplinary management that integrates psychiatry and immunology. Greater recognition of these neuropsychiatric dimensions could improve patient outcomes and guide future therapeutic strategies.**

Introduction

Mast Cell Activation Syndrome (MCAS) is a chronic multisystem disorder caused by inappropriate release of mast cell mediators, including histamine, prostaglandins, leukotrienes, and cytokines. These mediators drive a wide range of symptoms affecting dermatologic, gastrointestinal, cardiovascular, respiratory, and neurologic systems. Unlike classical allergic conditions, MCAS symptoms are heterogeneous and unpredictable, often fluctuating in severity and presentation. Increasingly, patients and clinicians have also reported psychiatric and neurocognitive manifestations, such as anxiety, depression, and brain fog, which can be as debilitating as physical symptoms but remain underrecognized in clinical practice.

Recent surveys by The Mast Cell Disease Society (TMS) and Mast Cell Action UK highlight the high burden of psychiatric comorbidity in MCAS. Over half of respondents reported experiencing clinically significant depression or anxiety, and more than two-thirds endorsed persistent cognitive dysfunction. These findings mirror patterns observed in other chronic inflammatory conditions, in which immune dysregulation contributes to both physical illness and psychiatric vulnerability. Yet, despite growing evidence of neuropsychiatric involvement, systematic studies investigating the biological mechanisms and clinical consequences of these symptoms in MCAS remain limited.

Emerging research suggests several plausible pathways linking mast cell activation to psychiatric outcomes. Mast cells are strategically located at the blood–brain barrier and interact closely with neurons and microglia. Through release of pro-inflammatory cytokines such as IL-6, TNF-α, and IL-1β, mast cells may amplify neuroinflammation, a process strongly implicated in the pathophysiology of depression. Histamine, a key mast cell mediator, also functions as a neurotransmitter regulating arousal, attention, and mood, suggesting that dysregulated histamine release could contribute directly to psychiatric symptoms. Coupled with the psychosocial stress of chronic illness, frequent misdiagnosis, and prolonged uncertainty, these biological factors may explain the disproportionately high prevalence of depression and anxiety among MCAS patients.

The present study seeks to explore the neuropsychiatric implications of MCAS by reviewing available patient-reported outcomes, survey data, and mechanistic evidence. By synthesizing clinical and biological

perspectives, this research aims to clarify the role of mast cell dysfunction in psychiatric morbidity and to emphasize the importance of interdisciplinary care that integrates immunology and mental health.

Methods

Study Design

This study is a cross-sectional analysis of patient-reported outcomes, drawing on data from large-scale surveys conducted by The Mast Cell Disease Society (TMS) and Mast Cell Action UK, as well as published clinical case series. Instead of collecting new data, we synthesized psychiatric symptom prevalence rates and neuropsychiatric outcomes reported in existing datasets. The focus was reframed to specifically examine depression, anxiety, and cognitive impairment as outcomes in patients with clinician-confirmed MCAS or related mast cell disorders. All survey data were collected anonymously with electronic informed consent.

Data Sources

Key data sources included the 2018 TMS MCAS Patient Survey (N ≈ 1,600) and the 2022 Mast Cell Action UK Survey (N = 680). Both surveys included items on psychiatric symptoms, cognitive impairment (“brain fog”), and impacts on daily functioning. Supplemental evidence came from Afrin et al.’s 2018 clinical case series (N = 100) and additional case reports describing neuropsychiatric manifestations. Inclusion criteria were: (1) clinician-confirmed MCAS diagnosis, (2) report of depression, anxiety, or cognitive impairment, and (3) availability of quantitative or qualitative outcome data.

Measures

Outcomes included self-reported depression and anxiety (diagnosis or symptom endorsement), cognitive impairment ratings, and mental health–related quality of life domains. When available, standardized tools such as PROMIS Global Mental Health were included. Comorbidities of interest included postural orthostatic tachycardia syndrome (POTS), Ehlers-Danlos Syndrome (EDS), and migraines, given their overlap with neuropsychiatric symptoms.

Analysis

Descriptive statistics summarized prevalence of psychiatric outcomes across datasets. Between-study comparisons were made to examine consistency in reported depression and anxiety rates. Where available, chi-square tests were used to compare prevalence rates between MCAS cohorts and reference general population estimates. Mechanistic findings from laboratory-based studies were narratively synthesized to complement patient-reported outcomes.

Limitations

Because this study relied on secondary analysis of self-reported survey data, findings may be subject to recall bias and selection bias (patients active in advocacy groups may have more severe disease). Psychiatric diagnoses were often patient-reported rather than formally confirmed by clinicians, limiting diagnostic precision. Despite these limitations, these datasets represent the most comprehensive sources available on neuropsychiatric outcomes in MCAS and provide a foundation for future prospective studies.

Results

Respondent Characteristics

Across the two TMS surveys, respondents were predominantly female (70–75%) with a mean age in the mid-40s. The mean reported diagnostic delay was 6.5 years (median 3). Comorbidities included Postural Orthostatic Tachycardia Syndrome (30–40%), Ehlers-Danlos Syndrome (20–30%), migraines, and asthma.

Table 1. Respondent Characteristics from TMS Surveys

Variable	2010 Survey (N=420)	2-18 Survey (N≈1,600)
Female Respondants	~72%	~75%
Mean age (years)	42	45
Mean diagnostic delay (years)	6.5	6.5
Median diagnostic delay (years)	3	3
POTS prevalence	34%	38%
EDS prevalence	22%	28%

Psychiatric Outcomes

Survey data indicated that >50% of patients reported clinically significant depression or anxiety. Fatigue and cognitive impairment were among the most disabling symptoms.

Table 2. Reported Psychiatric Outcomes in MCAS Patients (2018 Survey)

Outcome	Prevalence

Depression (self-reported)	**52%**
Anxiety disorders	**49%**
Sleep disturbance	**60%**
Cognitive dysfunction	**65%**
Fatigue	**72%**

Mechanistic Pathways

Evidence supports several biologically plausible pathways by which mast cells contribute to psychiatric morbidity.

Table 3. Neuroinflammatory Pathways Linking Mast Cells to Depression

Mechanism	Effect on Mental Health	Supporting Evidence
Histamine dysregulation	Alters mood, arousal, and circadian rhythms	Lindley et al., 2022【1】
Cytokine release (IL-6, TNF-α)	Promotes depressive phenotypes	Miller & Raison, 2016【2】
Blood–brain barrier permeability	Facilitates neuroinflammation	Skaper et al., 2017【3】
Mast cell–microglia interactions	Amplify stress-related inflammatory cascades	Dong et al., 2021【4】

Neuroinflammatory Pathways

Mechanistic studies suggest that mast cells contribute significantly to psychiatric morbidity through several converging biological mechanisms. Dysregulation of histamine signaling can alter mood and arousal circuits, while excessive release of pro-inflammatory cytokines such as IL-6, TNF-α, and IL-1β has been repeatedly associated with depressive phenotypes in neuropsychiatric research. In addition, mast cell mediators increase blood–brain barrier permeability, thereby facilitating the entry of inflammatory molecules into the central nervous system and amplifying neuroinflammation. Finally, direct mast cell–microglia interactions have been shown to intensify neuroinflammatory cascades that are strongly implicated in stress response and psychiatric disease.

Clinical Observations

Patients commonly reported psychiatric symptoms fluctuating with MCAS flares, supporting a temporal relationship between mediator release and mental health outcomes. Case reports document improvement in mood and cognition following mast cell stabilizer therapy (e.g., cromolyn sodium, antihistamines), though psychiatric endpoints remain under-studied in controlled trials.

Discussion

This review highlights the psychiatric burden of MCAS and the mechanistic plausibility of mast cell–driven neuroinflammation in depression and anxiety. Survey data underscore the magnitude of psychiatric comorbidity, with the majority of patients reporting mental health impairments that compound physical symptoms.

Mechanistic evidence from both clinical and preclinical studies implicates mast cells in regulating neuroinflammation, neurotransmitter balance, and blood–brain barrier function. The release of histamine and cytokines such as IL-6, TNF-α, and IL-1β have been consistently associated with depressive phenotypes. In parallel, mast cell–microglia cross-talk creates a feed-forward inflammatory loop, exacerbating stress-related responses.

These findings suggest that mental health care should be integrated into the management of MCAS. Routine screening for depression, anxiety, and cognitive dysfunction may allow earlier interventions, improving patient outcomes. Multidisciplinary approaches combining immunology, psychiatry, and neurology may be necessary to address the dual somatic and psychiatric burden of the disorder.

Conclusion

MCAS is a complex, multisystem condition with underrecognized psychiatric implications. Depression, anxiety, fatigue, and cognitive impairment are highly prevalent and may be mechanistically linked to mast cell–driven neuroinflammation. Early recognition and management of psychiatric comorbidity should be prioritized alongside physical symptom control. Further longitudinal studies are warranted to clarify causality and guide therapeutic strategies.

Acknowledgments

I would like to acknowledge Jenny M. Montejo, M.D. (Mayo Clinic) for her mentorship, The Mast Cell Disease Society for access to survey data, and my mother, whose experience with MCAS inspires my research and advocacy.

References

1. Lindley M, Heifetz A, Wulff H. Histamine dysregulation and neuropsychiatric disease. *Front Neurosci*. 2022;16:841225.
2. Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. *Nat Rev Immunol*. 2016;16(1):22-34.
3. Skaper SD, Facci L, Giusti P. Mast cells, glia and neuroinflammation: partners in crime? *Immunology*. 2017;142(3):335-347.
4. Dong X, Dong X, Li J, et al. Mast cell–microglia interaction in stress and neuroinflammation. *Brain Behav Immun*. 2021;95:398-409.
5. Afrin LB, Weinstock LB, Molderings GJ. Diagnosis of mast cell activation syndrome: a global “consensus-2”. *J Allergy Clin Immunol Pract*. 2020;8(9):3131-3140.
6. Theoharides TC, Tsilioni I, Ren H. Recent advances in our understanding of mast cell activation— or should it be mast cell mediator disorders? *Expert Rev Clin Immunol*. 2019;15(6):639-656.
7. Valent P, Akin C, Bonadonna P, et al. Proposed diagnostic algorithm for patients with suspected mast cell activation syndrome. *J Allergy Clin Immunol Pract*. 2019;7(4):1125-1133.